These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 16472048)

  • 1. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist.
    Kimberly MM; Cooper GR; Myers GL
    Diabetes Technol Ther; 2006 Feb; 8(1):37-44. PubMed ID: 16472049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial.
    Schaumberg DA; Glynn RJ; Jenkins AJ; Lyons TJ; Rifai N; Manson JE; Ridker PM; Nathan DM
    Circulation; 2005 May; 111(19):2446-53. PubMed ID: 15867184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus.
    Pfützner A; Standl E; Strotmann HJ; Schulze J; Hohberg C; Lübben G; Pahler S; Schöndorf T; Forst T
    Clin Chem Lab Med; 2006; 44(5):556-60. PubMed ID: 16681424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
    Piechota W; Piechota W
    Pol Merkur Lekarski; 2005 May; 18(107):511-5. PubMed ID: 16161944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM; Ryan MC; Boyle AJ
    Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and cardiovascular risk markers.
    Erdmann E
    Curr Med Res Opin; 2005; 21 Suppl 1():S21-8. PubMed ID: 15811196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Sensitivity C-Reactive Protein and Statin Initiation.
    Trpkovic A; Stanimirovic J; Rizzo M; Resanovic I; Soskic S; Jevremovic D; Isenovic ER
    Angiology; 2015 Jul; 66(6):503-7. PubMed ID: 25053677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of central obesity, low high-density lipoprotein cholesterol and C-reactive protein polymorphisms on C-reactive protein levels during treatment with Rosuvastatin (10 mg Daily).
    Hu M; Lee MH; Mak VW; Tomlinson B
    Am J Cardiol; 2010 Dec; 106(11):1588-93. PubMed ID: 21094359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Screening for hyperlipidemia in cardiovascular high-risk patients in austrian diabetes ambulances].
    Brath H; Wascher TC; Kästenbauer T; Toplak H
    MMW Fortschr Med; 2012 Jun; 154 Suppl 2():41-7. PubMed ID: 23424754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trials investigating the relationship between dietary pattern and high-sensitivity C-reactive protein: a systematic review.
    Pickworth CK; Deichert DA; Corroon J; Bradley RD
    Nutr Rev; 2019 Jun; 77(6):363-375. PubMed ID: 31222367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Ridker PM; Wilson PW; Grundy SM
    Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.
    Özyilmaz A; Boersma C; Visser ST; Postma MJ; de Jong-van den Berg LT; Lambers-Heerspink HJ; de Jong PE; Gansevoort RT
    Eur J Prev Cardiol; 2016 May; 23(8):847-55. PubMed ID: 26358992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-sensitivity C-reactive protein in every chart? The use of biomarkers in individual patients.
    Ben-Yehuda O
    J Am Coll Cardiol; 2007 May; 49(21):2139-41. PubMed ID: 17531664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.